Fanconi Anemia

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


WHO WE ARE — Seattle Cancer Care Alliance is a world-class cancer treatment center that unites doctors from Fred Hutch, UW Medicine and Seattle Children's. Learn More

Overview

Fanconi anemia (FA) is a rare, inherited blood disorder that causes the bone marrow to stop making enough new blood cells. It also causes the bone marrow to make abnormal blood cells, which can lead to serious health problems, such as cancer.

FA can affect many of your body's organs, tissues, and systems. Children who inherit FA are at higher risk of being born with deformities and are at higher risk for some cancers and other serious health problems. As an inherited disease, children should be tested if one of their brothers or sisters has the disease.

Outstanding Care Team

The Fanconi Anemia Center is one of the few places in the United States where families dealing with FA can receive comprehensive care plus access to the newest specialized treatments. We have the experience and the range of services to handle the complex needs of any FA patient. This depth and quality of FA resources derives directly from our three founding organizations:

  • Seattle Children’s Hospital provides top-rated care in all the specialties needed by FA patients (ranked 7th nationally by US News & World Report).
  • Fred Hutchinson Cancer Research Center has created many of the techniques now used worldwide to transplant patients with FA and other bone marrow failure disorders. 
  • University of Washington Medical Center is a hub of innovative research on new genomic therapies for rare diseases such as FA.

Many FA patients will benefit from care at an FA center that offers high quality, multidisciplinary specialty services and standard transplant as well as a direct line to emerging treatments—therapies such as alternative donor transplants (we are among the most successful in the nation at such unmatched transplants) and new gene therapy techniques (our FA Center recently began the world’s first lentivirus vector-based gene therapy trial for FA patients).

Our pediatric bone marrow experts and transplant specialists are ready to assist patients of any age, newly diagnosed or previously treated, and with any special complications or conditions.